mortality/aging
• median survival is 146 days
|
neoplasm
• all develop a myeloproliferative neoplasm
• these myeloproliferative neoplasms can be transplanted by transfer of either unfractionated bone marrow cells or LSK cells but not by transfer of MEP or granulocyte/macrophage progenitor cells
• however, acute leukemia is not detected
|
hematopoietic system
N |
• despite the increase in megakaryocyte numbers no increases in platelet counts are detected
|
• expansion of the megakaryocytic/erythroid progenitor (MEP) population
• disproportional increase in the number of erythroid progenitors relative to other myeloid progenitor
|
• increase in the number of erythroid precursors in the bone marrow and spleen
• marked erythroid hyperplasia in the splenic red pulp
|
• prominent splenic extramedullary hematopoiesis
|
• megakaryocytes with atypical nuclear features are present in the bone marrow
|
• mild hyperplasia in the splenic red pulp
|
• overall effacement of the normal architecture
|
• marked erythroid and mild megakaryocytic hyperplasia in the splenic red pulp
|
• MEPs show EPO hypersensitivity
• gene set enrichment analysis indicates that hematopoietic differentiation in the LSK compartment is altered
|
• megakaryocytes with prominent emperipolesis are present in the bone marrow
|
immune system
• overall effacement of the normal architecture
|
• marked erythroid and mild megakaryocytic hyperplasia in the splenic red pulp
|
growth/size/body
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
polycythemia vera | DOID:8997 |
OMIM:263300 |
J:160883 |